Tag Archives: GlaxoSmithKline

GSK Scores High in Market Access

GlaxoSmithKline ranked number one in a study of pharmaceutical companies offering access to medicines to emerging and developing nations, proving that the UK drug giant has a far stronger grasp on new markets than its US and Japanese counterparts. The study ranks 20 companies based on significant criteria including pricing, patents and intellectual properties, capacity […]
Posted in Emerging Markets, Strategy | Also tagged , , , , , , | Leave a comment

AstraZeneca to Slash 8,000 More Jobs (Updated 2/3/10)

Last year, AstraZeneca announced the elimination of some 15,000 jobs. Last Thursday, the London-based company revealed that it plans to lay off another 8,000 by 2014—this despite global revenue growth of 4 percent for 2009. Much of the drive for this addition labor sculpting stems from AZ’s desire to streamline its R&D; the company will […]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment

One to Watch: Q&A with Paul Dyer

Paul Dyer, eMedia Director, WeissComm Group (WCG), is already on his way to the top not only on PR News’ 15 to watch list, but also as an emerging leader in the online healthcare landscape. At 26, Paul Dyer has a long list of accolades that most young professionals his age only dream about. As […]
Posted in Marketing, People | Also tagged , , , , , , | Leave a comment

The Trouble with Transparency

Guest blog by Jacky Law A couple of weeks ago I attended an industry awards dinner and had an interesting conversation with an eminent doctor who shall remain nameless. The doctor in question works in a highly specialized area and frequently talks about her research at conferences around the world. She always travels first-class and […]
Posted in Guest Blog, Strategy | Also tagged , , , , , , | Leave a comment

Pharma Celebrates its Own

At the gala ceremony for the 2009 Prix Galien USA award on October 1, a paradigm shift in drug development took center stage. “The most successful new [cancer] therapies will be based on a precise molecular understanding of disease basis—that’s exactly what we did with Gleevec,” said keynote speaker Brian Druker, director of the Oregon […]
Posted in Events | Also tagged , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta